The study used evidence gathered from patient experiences rather than a controlled trial, Novo said.

Eli Lilly's retatrutide is still in clinical trials. But gym bros are already using a version of the weight-loss drug, amid a growing DIY culture in fitness circles.

New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

A Fierce Battle for Weight-Loss Supremacy The weight-loss drug market has become a battleground, ignited by the runaway ...

Eli Lilly announced this week that its new weight-loss pill, orforglipron, cleared its latest Phase 3 trial, bringing it closer to potential Food and Drug Administration (FDA) approval. Compared with ...

Eli Lilly's orforglipron outshines Novo Nordisk's oral semaglutide with efficacy & scalability, promising growth in the ...

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to ...

Eli Lilly has temporarily paused shipments of its weight-loss drug Mounjaro in the UK, ahead of a new price hike for the ...

The bear case for Eli Lilly has now played out following the reaction to the drugmaker’s oral obesity drug trial, an analyst ...

Explore the latest healthcare market shifts: gains, losses, policy impacts, and major acquisitions, including Eli Lilly's obesity drug progress.

With Wall Street still enthralled by tech and AI stocks, Eli Lilly is a speculative play with plenty of benefits to be reaped from diversification. While it's important to keep an ear to the ground in ...

Eli Lilly is "confident" it can reach the 750 job number it stated in December after an agreement with the state provides tax credits for 560 jobs.